Impact of hormone therapy on laboratory values in transgender patients

Jeffrey A. SoRelle, Rhoda Jiao, Emily Gao, Jonas Veazey, Ithiel Frame, Andrew M. Quinn, Philip Day, Patti Pagels, Nora Gimpel, Khushbu K Patel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: For transgender individuals taking hormone therapy (HT), data on laboratory values are limited, and the effects on laboratory values cannot be easily predicted. We evaluated the impact on common laboratory analytes in transgender individuals before and after initiation of HT. METHODS: We conducted a retrospective chart review of transgender patients identified at transgender-specific clinics at an urban county hospital and community clinic. Laboratory data were collected on hormone concentrations, hematologic parameters, electrolytes, lipids, and liver and renal markers before and after initiation of HT. RESULTS: We identified 183 transgender women (TW) and 119 transgender men (TM) for whom laboratory data were available. In all, 87 TW and 62 TM had baseline laboratory data, and data were also available for 133 TW and 89 TM on HT for 6 months. The most significant changes were seen in red blood cell count, hemoglobin concentration, hematocrit, and creatinine levels after 6 months of HT, which increased in TM and decreased in TW after HT (P 0.005; d index 0.6). Alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels increased in TM; however, the effect size was small (d index 0.5). Calcium, albumin, and alkaline phosphatase levels significantly decreased in TW (P 0.001; d 0.6). Additionally, TM were found to have increased triglycerides and decreased HDL levels (P 0.005; d 0.6). CONCLUSIONS: Changes occur in several common laboratory parameters for patients on HT. Some laboratory values changed to match the gender identity, whereas others remained unchanged or were intermediate from the baseline values. These findings will help guide interpretation of laboratory test results in transgender patients taking HT.

Original languageEnglish (US)
Pages (from-to)170-179
Number of pages10
JournalClinical Chemistry
Volume65
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Transgender Persons
Hormones
Therapeutics
Alkaline Phosphatase
Aspartate Aminotransferases
Alanine Transaminase
Liver
Electrolytes
Albumins
Creatinine
Hemoglobins
Triglycerides
Blood
Cells
County Hospitals
Erythrocyte Count
Calcium
Lipids

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Impact of hormone therapy on laboratory values in transgender patients. / SoRelle, Jeffrey A.; Jiao, Rhoda; Gao, Emily; Veazey, Jonas; Frame, Ithiel; Quinn, Andrew M.; Day, Philip; Pagels, Patti; Gimpel, Nora; Patel, Khushbu K.

In: Clinical Chemistry, Vol. 65, No. 1, 01.01.2019, p. 170-179.

Research output: Contribution to journalArticle

SoRelle, JA, Jiao, R, Gao, E, Veazey, J, Frame, I, Quinn, AM, Day, P, Pagels, P, Gimpel, N & Patel, KK 2019, 'Impact of hormone therapy on laboratory values in transgender patients', Clinical Chemistry, vol. 65, no. 1, pp. 170-179. https://doi.org/10.1373/clinchem.2018.292730
SoRelle JA, Jiao R, Gao E, Veazey J, Frame I, Quinn AM et al. Impact of hormone therapy on laboratory values in transgender patients. Clinical Chemistry. 2019 Jan 1;65(1):170-179. https://doi.org/10.1373/clinchem.2018.292730
SoRelle, Jeffrey A. ; Jiao, Rhoda ; Gao, Emily ; Veazey, Jonas ; Frame, Ithiel ; Quinn, Andrew M. ; Day, Philip ; Pagels, Patti ; Gimpel, Nora ; Patel, Khushbu K. / Impact of hormone therapy on laboratory values in transgender patients. In: Clinical Chemistry. 2019 ; Vol. 65, No. 1. pp. 170-179.
@article{67f7ea65ef0046c28b3e60b7596bdfb3,
title = "Impact of hormone therapy on laboratory values in transgender patients",
abstract = "BACKGROUND: For transgender individuals taking hormone therapy (HT), data on laboratory values are limited, and the effects on laboratory values cannot be easily predicted. We evaluated the impact on common laboratory analytes in transgender individuals before and after initiation of HT. METHODS: We conducted a retrospective chart review of transgender patients identified at transgender-specific clinics at an urban county hospital and community clinic. Laboratory data were collected on hormone concentrations, hematologic parameters, electrolytes, lipids, and liver and renal markers before and after initiation of HT. RESULTS: We identified 183 transgender women (TW) and 119 transgender men (TM) for whom laboratory data were available. In all, 87 TW and 62 TM had baseline laboratory data, and data were also available for 133 TW and 89 TM on HT for 6 months. The most significant changes were seen in red blood cell count, hemoglobin concentration, hematocrit, and creatinine levels after 6 months of HT, which increased in TM and decreased in TW after HT (P 0.005; d index 0.6). Alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels increased in TM; however, the effect size was small (d index 0.5). Calcium, albumin, and alkaline phosphatase levels significantly decreased in TW (P 0.001; d 0.6). Additionally, TM were found to have increased triglycerides and decreased HDL levels (P 0.005; d 0.6). CONCLUSIONS: Changes occur in several common laboratory parameters for patients on HT. Some laboratory values changed to match the gender identity, whereas others remained unchanged or were intermediate from the baseline values. These findings will help guide interpretation of laboratory test results in transgender patients taking HT.",
author = "SoRelle, {Jeffrey A.} and Rhoda Jiao and Emily Gao and Jonas Veazey and Ithiel Frame and Quinn, {Andrew M.} and Philip Day and Patti Pagels and Nora Gimpel and Patel, {Khushbu K}",
year = "2019",
month = "1",
day = "1",
doi = "10.1373/clinchem.2018.292730",
language = "English (US)",
volume = "65",
pages = "170--179",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "1",

}

TY - JOUR

T1 - Impact of hormone therapy on laboratory values in transgender patients

AU - SoRelle, Jeffrey A.

AU - Jiao, Rhoda

AU - Gao, Emily

AU - Veazey, Jonas

AU - Frame, Ithiel

AU - Quinn, Andrew M.

AU - Day, Philip

AU - Pagels, Patti

AU - Gimpel, Nora

AU - Patel, Khushbu K

PY - 2019/1/1

Y1 - 2019/1/1

N2 - BACKGROUND: For transgender individuals taking hormone therapy (HT), data on laboratory values are limited, and the effects on laboratory values cannot be easily predicted. We evaluated the impact on common laboratory analytes in transgender individuals before and after initiation of HT. METHODS: We conducted a retrospective chart review of transgender patients identified at transgender-specific clinics at an urban county hospital and community clinic. Laboratory data were collected on hormone concentrations, hematologic parameters, electrolytes, lipids, and liver and renal markers before and after initiation of HT. RESULTS: We identified 183 transgender women (TW) and 119 transgender men (TM) for whom laboratory data were available. In all, 87 TW and 62 TM had baseline laboratory data, and data were also available for 133 TW and 89 TM on HT for 6 months. The most significant changes were seen in red blood cell count, hemoglobin concentration, hematocrit, and creatinine levels after 6 months of HT, which increased in TM and decreased in TW after HT (P 0.005; d index 0.6). Alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels increased in TM; however, the effect size was small (d index 0.5). Calcium, albumin, and alkaline phosphatase levels significantly decreased in TW (P 0.001; d 0.6). Additionally, TM were found to have increased triglycerides and decreased HDL levels (P 0.005; d 0.6). CONCLUSIONS: Changes occur in several common laboratory parameters for patients on HT. Some laboratory values changed to match the gender identity, whereas others remained unchanged or were intermediate from the baseline values. These findings will help guide interpretation of laboratory test results in transgender patients taking HT.

AB - BACKGROUND: For transgender individuals taking hormone therapy (HT), data on laboratory values are limited, and the effects on laboratory values cannot be easily predicted. We evaluated the impact on common laboratory analytes in transgender individuals before and after initiation of HT. METHODS: We conducted a retrospective chart review of transgender patients identified at transgender-specific clinics at an urban county hospital and community clinic. Laboratory data were collected on hormone concentrations, hematologic parameters, electrolytes, lipids, and liver and renal markers before and after initiation of HT. RESULTS: We identified 183 transgender women (TW) and 119 transgender men (TM) for whom laboratory data were available. In all, 87 TW and 62 TM had baseline laboratory data, and data were also available for 133 TW and 89 TM on HT for 6 months. The most significant changes were seen in red blood cell count, hemoglobin concentration, hematocrit, and creatinine levels after 6 months of HT, which increased in TM and decreased in TW after HT (P 0.005; d index 0.6). Alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels increased in TM; however, the effect size was small (d index 0.5). Calcium, albumin, and alkaline phosphatase levels significantly decreased in TW (P 0.001; d 0.6). Additionally, TM were found to have increased triglycerides and decreased HDL levels (P 0.005; d 0.6). CONCLUSIONS: Changes occur in several common laboratory parameters for patients on HT. Some laboratory values changed to match the gender identity, whereas others remained unchanged or were intermediate from the baseline values. These findings will help guide interpretation of laboratory test results in transgender patients taking HT.

UR - http://www.scopus.com/inward/record.url?scp=85059500918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059500918&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2018.292730

DO - 10.1373/clinchem.2018.292730

M3 - Article

C2 - 30518663

AN - SCOPUS:85059500918

VL - 65

SP - 170

EP - 179

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 1

ER -